Equatorial Guinea vs Nepal: Average cost of multi drug-resistant tuberculosis treatment
Equatorial Guinea
1,500 constant 2022 US$
in 2024
Nepal
1,526 constant 2022 US$
in 2024
Equatorial Guinea rank
34th
Nepal rank
33rd
Average cost of multi drug-resistant tuberculosis treatment over time
- Equatorial Guinea
- Nepal
How they compare
Nepal currently reports 1,526 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea, a difference of 26 constant 2022 US$.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Nepal ahead.
Equatorial Guinea ranks 34th and Nepal ranks 33rd of 92 countries.
Across the 2 decades both report, Equatorial Guinea averaged higher in 1 and Nepal in 1.
Head to head by decade
| Decade | Equatorial Guinea | Nepal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,000 constant 2022 US$ | 1,038 constant 2022 US$ | 38 constant 2022 US$ | Nepal |
| 2020s | 1,362 constant 2022 US$ | 1,226 constant 2022 US$ | 136 constant 2022 US$ | Equatorial Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Equatorial Guinea or Nepal?
- Nepal, at 1,526 constant 2022 US$ against 1,500 constant 2022 US$ in Equatorial Guinea as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Equatorial Guinea and Nepal?
- 26 constant 2022 US$, with Nepal ahead.
- How many years of comparable data are there for Equatorial Guinea and Nepal?
- 6 years are reported by both, from 2019 to 2024.
- How do Equatorial Guinea and Nepal rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Equatorial Guinea ranks 34th and Nepal ranks 33rd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.